Fulgent Genetics (FLGT) CSO has shares withheld to cover RSU taxes

Rhea-AI Filing Summary

Fulgent Genetics Chief Scientific Officer Hanlin Gao reported tax-withholding share dispositions related to restricted stock unit vesting. On February 26, 2026 and March 1, 2026, several small blocks of common stock were withheld at prices of $24.76 and $15.33 per share to cover tax obligations, leaving Gao with direct ownership of just under 1.0 million shares after these administrative transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gao Hanlin

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		F		897(1)	D	$24.76	1,002,080	D
Common Stock	03/01/2026		F		1,018(2)	D	$15.33	1,001,062	D
Common Stock	03/01/2026		F		6,410(3)	D	$15.33	994,652	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.

2. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022.

3. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.

	/s/ Paul Kim as Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Fulgent Genetics (FLGT) report for Hanlin Gao?

Fulgent Genetics reported that Chief Scientific Officer Hanlin Gao had common shares withheld to cover taxes from restricted stock unit vesting. The Form 4 lists multiple small tax-withholding dispositions, all coded “F,” rather than open-market purchases or sales, and reflects continued significant direct ownership.

Were the Fulgent Genetics (FLGT) insider transactions open-market sales?

No, the reported transactions were not open-market sales. The shares were withheld to satisfy tax withholding obligations triggered by vesting of previously granted restricted stock units, as indicated by transaction code “F” and detailed footnotes describing the RSU grant and vesting dates.

How many types of transactions did Fulgent Genetics (FLGT) disclose for Hanlin Gao?

The filing discloses only one type of transaction for Hanlin Gao: tax-withholding dispositions of common stock tied to restricted stock unit vesting. All entries use transaction code “F,” indicating payment of tax liability by delivering shares rather than discretionary market trading activity.

What prices were used for the Fulgent Genetics (FLGT) tax-withholding share dispositions?

The tax-withholding dispositions used prices of $24.76 and $15.33 per common share. These prices applied on different transaction dates when restricted stock units vested, determining how many shares were withheld to cover Gao’s associated tax obligations instead of a cash payment.

Does Hanlin Gao still hold a significant stake in Fulgent Genetics (FLGT) after these transactions?

Yes. After the tax-withholding dispositions, the Form 4 shows Hanlin Gao continuing to hold roughly one million shares of Fulgent Genetics common stock directly. The reported transactions represent small portions of his holdings, used solely to satisfy tax obligations from RSU vesting.

What do the footnotes in the Fulgent Genetics (FLGT) Form 4 explain about these insider transactions?

The footnotes explain that shares were withheld to cover tax obligations arising from vesting of restricted stock units granted in 2022, 2024, and 2025. Each note links the withholding to a specific prior RSU grant that had already been reported on earlier Form 4 filings.